For the second quarter of 2026, analysts expect GRAIL to report a consensus revenue of $42.39 million and a loss per share of $2.66, with the stock currently trading at $70.33 compared to an average price target of $67.78.
The central focus for investors is the commercial adoption of the Galleri multi-cancer early detection test and total screening revenue growth, which is projected to increase by approximately 19% year-over-year.
Market sentiment remains guarded following the February 2026 announcement that the large-scale NHS-Galleri trial failed to meet its primary stage-reduction endpoint. Management is expected to provide further details on commercial partnerships and clinical results from the PATHFINDER 2 study to reassure shareholders of long-term scalability and regulatory progress.